Adipose-Derived Stem Cells Exosomes Improve Fat Graft Survival by Promoting Prolipogenic Abilities through Wnt/β-Catenin Pathway

Kexin Chen, Jiachao Xiong, Sha Xu, Minliang Wu, Chunyu Xue, Minjuan Wu, Chuan Lv, and Yuchong Wang

1Department of Plastic Surgery, Changhai Hospital, Naval Military Medical University, Shanghai 200433, China
2Department of Plastic Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China
3Institute of Translational Medicine, Naval Military Medical University, Shanghai 200433, China
4Department of Histology and Embryology, Naval Military Medical University, Shanghai 200433, China
5School of Life Sciences and Technology, Tongji University, Shanghai 200092, China

Correspondence should be addressed to Minjuan Wu; minjuanwu@163.com, Chuan Lv; drlvchuan@163.com, and Yuchong Wang; drwangyc@163.com

Received 5 January 2022; Revised 22 March 2022; Accepted 29 March 2022; Published 6 May 2022

Academic Editor: Yibo Gan

Copyright © 2022 Kexin Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Autologous fat grafting has been widely used in plastic surgery in recent years, but the unstable retention of fat graft has always been a key clinical problem. Adipose tissue has poor tolerant to ischemia, so the transplanted adipose tissue needs to rebuild blood supply at an early stage in order to survive stably. Our previous study has found that comparing to human foreskin fibroblast exosome (HFF-Exo), human adipose-derived stem cells exosome (hADSC-Exo) can significantly improve the proliferation of vascular endothelial cells and the angiogenic effect of artificial dermal preconstructed flaps. Therefore, the ability of hADSC-Exo to improve the retention of adipose grafts and its potential regenerative mechanism aroused our strong interest. In this study, we applied hADSC-Exo and HFF-Exo to adipose grafts and explored the potential regeneration mechanism through various means such as bioinformatics, immunofluorescence, immunohistochemistry, and adipogenic differentiation. The results showed that hADSC-Exo can significantly promote grafts angiogenesis and adipogenic differentiation of ADSC to improve the retention of fat grafts and may downregulate the Wnt/β-catenin signaling pathway to promote the adipogenic differentiation. In summary, our results provide a theoretical basis for the clinical translation of hADSC-Exo in fat grafting.

1. Introduction

Autologous fat grafting is widely used for various treatments in plastic surgery, such as depressed scarring, hemifacial atrophy, and facial rejuvenation, due to its good biocompatibility, low tissue rejection rate, and allergic reaction rate [1, 2]. However, the unstable retention of fat grafts has been a key clinical problem to be overcome. Adipose tissue has poor tolerant to ischemia, liposuction will result in the destruction of their original blood supply, and the transplanted adipose tissue needs to rebuild blood supply at an early stage in order to survive stably [3]. Yoshimura et al. [4] found that grafted fat mostly showed hematologic reconstruction only in the peripheral area, while the central area showed fat necrosis and resorption due to insufficient blood supply and a decrease in grafted tissue volume. Therefore, enhancing hematologic reconstruction in the early stages of fat grafting is one of the key factors to promote graft survival.

Adipose-derived stem cell (ADSC) is a type of stem cell derived from adipose tissue with multidirectional differentiation potential, which is widely used in the field of regenerative medicine in recent years because of its easy extraction and expansion and strong tissue repair activity [5]. Numerous studies [6, 7] have shown that cotransplantation of autologous adipose tissue with ADSC, which are capable of...
paracrine secretion of various cytokines to promote early vascularization, significantly improves the survival rate of adipose grafts. Interestingly, our previous study [8] found that ADSC can differentiate into vascular endothelial cells and enhance the proliferation and migration of vascular endothelial cells to promote the healing of chronic wounds. However, the tumorigenicity of ADSC and the storage and transport of cellular products are still controversial, and there is a lack of uniform standards for the application of ADSC products [9, 10]. Thus, ADSC does not have the conditions for clinical large-scale application.

Exosomes are a class secreted by cells into the extracellular matrix that can carry a variety of biological components such as proteins, lipids, and noncoding RNAs and can be transported to specific target cells or bound to the cell surface to mediate intercellular communication [11, 12]. ADSC-derived exosome (ADSC-Exo) has been used in ischemic injury diseases and has shown good vascular regenerative effects similar to ADSC, and has the advantages of no risk of tumor formation, high stability, and easy storage and transport, making it more promising for clinical application than ADSC-based cell therapies [13]. In our previous study [14], hADSC-Exo significantly promoted the proliferation of vascular endothelial cells and the angiogenic effect of artificial dermal preconstructed flaps compared to human foreskin fibroblast exosome (HFF-Exo). Therefore, the ability of hADSC-Exo to improve the retention of adipose grafts and its potential regenerative mechanism aroused our strong interest.

We therefore applied hADSC-Exo and HFF-Exo to adipose grafts in this study and found that hADSC-Exo were capable of significant graft vascular regeneration and adipogenic differentiation of ADSC to improve the retention of adipose grafts. Meanwhile, bioinformatics technology was used to explore the potential mechanisms of hADSC-Exo that promote the adipogenic differentiation of stem cells.

2. Material and Method

2.1. Identification of hADSC. The fourth passage of hADSC was selected for flow cytometry analysis for phenotypic identification of hADSC surface markers. CD90 and CD34 (BD Biosciences, San Jose, CA, USA) were used for flow cytometry analysis. We reported the staining steps previously [8].

2.2. Isolation of Exosome. Human adipose-derived stem cells (hADSC) with passages of 3-6 and human foreskin fibroblast (HFF) with passages of 3-6 were cultured for obtaining hADSC-Exo and HFF-Exo. The hADSC and HFF were cultured in low-glucose and high-glucose DMEM (HyClone, Utah, USA), respectively, and supplemented with 10% exosome-free fetal bovine serum (FBS) (Gibco, Grand Island, USA) and incubated with 5% CO2 at 37°C. Exosomes were isolated from hADSC and HFF culture medium by differential ultracentrifugation as previously described [15]. In brief, differential ultracentrifugation at 300,000g and 20,000g for 10 min, followed by 10,000g for 30 min, followed by 100,000g for 70 min twice were all performed at 4°C. The exosome pellets were finally resuspended in 100 μL of phosphate-buffered saline (PBS) and filtered with 0.22 sterile filter before use.

2.3. Verification of Exosome

2.3.1. Transmission Electron Microscopy (TEM). Exosomes were imaged by TEM to identify their morphology. The exosome sample with a volume of 20 μL was prepared and dropped on a copper mesh for 10 min and stained with 20 μL of 3% sodium phosphotungstate solution for 5 min. Then, copper mesh was dried at room temperature for 30 min. Finally, the sample was detected by TEM.

2.3.2. Nanoparticle Tracking Analysis (NTA). Particle size distribution of exosomes was identified by NTA (ZetaView, Particle Metrix, Germany). The exosome sample is diluted to the appropriate concentration using PBS and detected on the NTA.

2.3.3. Western Blotting. The western blotting instruction was described previously [8]. In brief, the proteins from each sample were extracted and transferred to a PVDF membrane (Cell Signaling Technology, MA, USA). The membrane was initially blocked in 5% bovine serum albumin for 2h and then incubated with primary CD63 (1:2000, Abcam, Cambridge, MA, UK), CD81 (1:1000, Cell Signaling Technology, USA), α-tubulin (1:1000, Cell Signaling Technology, MA, USA), VEGF-A antibody (1:1000, Abcam, Cambridge, MA, UK), and β-catenin (1:1000, Cell Signaling Technology, USA) at 4°C overnight, followed incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (1:3000, Beyotime, China). An Alpha Imager scanner (Tecan, Thermo Fisher Scientific, USA) was used to visualize the protein expression by chemiluminescence.

2.4. Fat Grafting In Vivo. A total of nine nude mice (6 weeks old, male) were purchased from the experimental animal center of Navy Military Medical University (Shanghai, China). All experiments were approved by the guidelines of the Health Sciences Animal Policy and Welfare Committee of Navy Military Medical University.

Transplanted fat from human subcutaneous adipose tissue samples were obtained from the abdominal liposuction of a healthy women in the Changhai Hospital affiliated with the Navy Military Medical University and were obtained with informed consent of the patient. Adipose tissue (0.5 mL) added with hADSC-Exo or HFF-Exo (100 μg) was subcutaneously injected in two recipient sites on the dorsal surface. The transplanted fat was observed at 1, 2, and 3 months postoperatively. The weight and volume of survive fat were assessed.

2.5. Immunohistochemistry and Immunofluorescence. Adipose tissues were excised at 1, 2, and 3 months after injection and analyzed by histological staining. The transplanted fat tissues were fixed with 4% polymethylene formaldehyde and embedded with paraffin. Hematoxylin and eosin were used for histological observation of the intrinsic structure of the grafted fat [16]. Transplanted fat angiogenesis and proliferative cells were observed by CD31 (1:50, Abcam,
UK) and Ki67 (1:500, Abcam, UK) immunohistochemical staining, respectively. Differentiated fat cells were observed by PPARγ (1:250, Abcam, UK) immunofluorescence staining. The immunohistochemical and immunofluorescence assays were performed as reported previously [8]. Immunohistochemical photomicrographs were obtained under a Pannoramic DESK (3D HISTECH, Hungary) and visualized by Pannoramic scanner, and immunofluorescence photomicrographs were obtained with a Zeiss fluorescence microscope (HLA100, Shanghai, China).

2.6. Cell Proliferation Assay. Cell proliferation rates were tested using a Cell Counting Kit-8 (CCK-8) assay (Beyotime, Jiangsu, China) and a 5-ethynyl-2 deoxyuridine (EdU) assay kit (RiboBio, Guangzhou, China). HUVECs (2000 cells/well) were seeded in a 96-well plate and incubated with different concentrations of hADSC-Exo (50, 100 or 200 μg/mL) or equivalent amount of PBS. Cell proliferation was analyzed at 24 h, 48 h, and 72 h after treatment. A 10 μL CCK8 reagent was added to each well, and the cells were incubated for 2 h at each time point. Then, OD value was verified by a microplate reader (Tecan, Thermo Scientific, USA) at 450 nm. The three independent experiments were performed. Based on the CCK8 data, we determined a suitable hADSC-Exo concentration for the follow-up experiment.

An EdU assay kit was performed to compare the proliferative effects hADSC-Exo and HFF-Exo on HUVEC. HUVECs (5 × 10^4 cells/well) were seeded in a 96-well plate and cultured to reach 70–80% confluence. Then, HUVECs were cocultured with the suitable hADSC-Exo concentrations and equal concentration of HFF-Exo for 72 h, and an EdU assay was performed according to the manufacturer’s instructions [17]. Proliferating HUVECs were stained with green fluorescent, and all cell nuclei were stained with blue fluorescent and observed with the Zeiss fluorescence microscope.

2.7. Cell Migration Assay. Transwell assays were performed to compare the migration effects hADSC-Exo and HFF-Exo on HUVEC. HUVECs (5 × 10^4 cells, 200 μL) resuspended in FBS-free medium and added to the Transwell insert, and the well was added with medium containing 5% exosome-free FBS and hADSC-Exo/HFF-Exo (800 μL). After culture for 18 h, HUVECs were fixed and stained with 0.1% crystalline violet, and the cells that did not cross the membrane were carefully wiped to remove and imaged. The migration cells were measured by using ImageJ software (Bethesda, MD, USA).

2.8. Adipogenic Differentiation Assay. The hADSCs (5 × 10^5 cells) were seeded in 12-well plates and cultured with medium containing 5% exosome-free FBS added with hADSC-Exo or HFF-Exo until their confluence was 70-80%. Then, the cells were cultured with adipogenic differentiation medium (Cyagen, Guangzhou, China) as the manufacturer’s instructions for 4 weeks [8]. Then, the cells were fixed and stained with oil red O. The stained cells were washed with PBS to away excess dye and imaged.

2.9. Differential Analysis of Gene Expression about Adipogenic Differentiation. The gene expression microarray dataset of hADSC during in vitro adipogenic differentiation (GSE61302), comprised of hADSC samples from 7-day adipogenic differentiation (n = 5), 21-day adipogenic differentiation (n = 6), and undifferentiated (n = 5), was downloaded from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo). The dataset was based on the GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array), and the mRNA expression data of 21-day adipogenic differentiated hADSC and undifferentiated control were downloaded and used for this study. The differential analysis of gene expression in late-stage adipogenic-differentiated hADSCs compared with undifferentiated cells was performed using the GEO2R analysis tool. An mRNA with a p value of <0.05 and a log FC value greater than ±1 was defined as a DEG, and the lists of upregulated and downregulated DEGs were collated for subsequent analysis.

2.10. Integration Analysis of Exosomes Contributing to Adipogenic Differentiation. The potential upregulated and downregulated target DEGs were selected, and the protein–protein interaction (PPI) networks were analyzed with the STRING database (https://string-db.org/). The hub genes in PPI networks were calculated by using the degree analysis method in the CytoHubba plug-in, and visualized by Cytoscape (version 3.9.0) software [18]. The DAVID database (https://david.ncifcrf.gov/home.jsp) was used to understand the biological function of genes, including gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment [19]. GO annotation analysis comprised of molecular function (MF), biological process (BP), and cell component (CC).

2.11. Statistical Analysis. Statistical analysis was performed using SPSS 26.0 and described as mean ± SD. Student’s t -test were used to examine statistical significance, and a p value of <0.05 was considered significant.

3. Results

3.1. Characterization of hADSC and Exosomes. To assess the surface marker phenotype of hADSC, the flow cytometry analysis was used to identify the purified hADSC. Approximately 99% of hADSCs were positive for CD90, but negative for CD34 (Figure 1(a)), which suggested that the cultured cells were ADSC. Exosome is a class of membranous vesicles about 30-150 nm in diameter extracted by various methods including ultracentrifugation, exclusion ultrafiltration, density gradient centrifugation, particle size separation, polymer precipitation, and immunoaffinity [15, 20]. In this study, the identification of exosomes was performed by TEM, NTA, and western blotting. TEM confirmed the typical morphology of the exosomes (Figure 1(b)), and NTA showed that the average diameter of hADSC-Exo was 139.5 ± 93.3 nm and HFF-Exo was 131.0 ± 52.2 nm (Figure 1(d)). Moreover, specific membrane protein markers CD63 and CD81 were
also highly expressed in both exosomes (Figure 1(c)). These results were all consistent with the characteristics of exosomes.

3.2. hADSC-Exo via Proangiogenic and Prolipogenetic Effects Improves Fat Graft Survival In Vivo. To assess the retention beneficial of hADSC-Exo on adipose grafts, nude mice were used as fat grafting models (Figure 2(a)). The grafts were harvested at 1, 2, and 3 months after fat grafting. A general observation of fat specimens at three time points revealed that the hADSC-Exo had better retention efficiency than HFF-Exo (Figure 2(b)). Then, the weight and volume of grafts were measured and found that the sizes of grafts decreased with the transplantation time, but the hADSC-Exo had better quantitative results than HFF-Exo (Figures 2(c)–2(h)), indicating an excellent effect of hADSC-Exo on grafted fat survival.

For microscopic assessment of the effect of hADSC-Exo in promoting the retention of adipose grafts, HE staining results (Figures 3(a) and 3(b)) revealed that the transplanted fat from hADSC-Exo groups had higher adipose number and more complete adipose morphological structure.
compared to the HFF-Exo groups. The degree of vascular regeneration and the number of proliferating cells are also important indicators to evaluate the retention of fat grafts. CD31<sup>+</sup> and Ki67 immunohistochemistry staining were performed and observed that the number of CD31-positive blood vessels and Ki67-positive proliferating cells in the hADSC-Exo group were significantly higher than that in the HFF-Exo group (Figures 3(c)–3(f)).

3.3. Proangiogenic Effect of hADSC-Exo In Vitro. To examine the proangiogenic capacity of hADSC-Exo and HFF-Exo, HUVEC proliferation and migration assays were performed. We first examined the effect of hADSC-Exo on HUVEC proliferation using CCK8 cell proliferation assay to determine the optimal concentration of exosomes for subsequent experiments. The results showed that 100 μg/mL of hADSC-Exo had the most significant promotion effect on HUVEC
proliferation, and this promotion effect persisted with increasing culture time (Figure 4(a)). Therefore, we used 100 μg/mL as concentration of hADSC-Exo and HFF-Exo for subsequent experiments. EdU proliferation assays and Transwell assays were used to evaluate the effect of both exosomes on HUVEC proliferation and migration, respectively. Notably, hADSC-Exo were able to promote HUVEC proliferation and migration more effectively than HFF-Exo (Figures 4(d)–4(g)).

VEGFA was initially shown to be an endothelial growth factor and a regulator of vascular permeability [21] and is closely associated with angiogenesis in a variety of conditions, including tumors and wounds [21, 22]. Thus, the protein expression of VEGFA was evaluated and found that hADSC-Exo group exhibited a higher degree of expression (Figures 4(b) and 4(c)). Our finding indicated that hADSC-Exo significantly promoted angiogenesis in adipose grafts.

3.4. Identification of Key Target Genes for Lipogenesis by hADSC-Exo. After observing that the hADSC-Exo group had superior adipose number and structural integrity, whether hADSC-Exo could promote adipogenic differentiation of the original ADSC in adipose tissue has aroused our strong interest. Therefore, we performed the immunofluorescence
staining of PPARγ in fat grafts to observe the status of adipogenic differentiation. The results showed that hADSC-Exo group had evidently significant PPARγ expression compared to the HFF-Exo group (p < 0.05) (Figures 5(a) and 5(b)).

To explore the potential mechanisms of adipogenic differentiation of ADSC, the GSE61302 expression profiling data were downloaded from the GEO database, and 1970 DEGs were identified by differential analysis between undifferentiated human primary ADSCs and mature adipocytes (Figures 5(c) and 5(d)). And the top ten upregulated and downregulated DEGs were selected and listed in Tables 1 and 2, respectively. Combined with our previous miRNA sequencing data on hADSC-Exo and HFF-Exo, a total of 605 DEGs may be targeted by hADSC-Exo in the process of adipogenic differentiation of ADSC (Figure 5(d)).

### 3.5. Comprehensive Functional Analysis of the Key Genes Targeted by hADSC-Exo

PPI network is significant for...
Figure 5: Comprehensive functional analysis of the key DEGs for lipogenesis targeted by hADSC-Exo. (a) The immunofluorescence staining revealed that hADSC-Exo group had evidently significant PPARγ expression compared to the HFF-Exo group. (b) The positive percentage of PPARγ expression in the fat grafts at 1, 2, and 3 months were calculated. (c) Volcano plot of the GSE61302 microarray dataset. (d) Venn diagram of key genes which may target by hADSC-Exo in the process of adipogenic differentiation of ADSC. (e) The mapped network for the top 20 hub genes in protein–protein interaction network. (f) The category of "biological process" of the target DEGs. (g) The category of "cellular component" of the target DEGs. (h) The category of "molecular function" of the target DEGs (*p < 0.05 and **p < 0.01).
understanding the mechanisms of biosignal and the functional connections between proteins under specific physiological conditions. In this study, the PPI network analysis was performed on the 605 key genes through STRING database. Subsequently, the hub genes with the highest degree of the first 20 nodes were obtained by the degree algorithm (Table 3) and visualized with Cytoscape software (Figure 5(e)). Regarding these hub genes, CTNNB1, AURKA, FOS, MKI67, and VWF were the top five hub genes.

Furthermore, GO annotation and KEGG pathway analysis were performed to further reveal the enrichment status of the DEGs in BP, MF, CC, and KEGG pathways through the DAVID database. With regard to the “biological process” category (Figure 5(f)), it was demonstrated that most of the DEGs were mainly involved in extracellular matrix organization, cell adhesion, and type I interferon signaling pathway. Regarding the CC (Figure 5(g)), the majority of the DEGs were mainly components of plasma membrane, proteinaceous extracellular matrix, integral component of plasma membrane, and costamere. Regarding the MF (Figure 5(h)), the DEGs were mostly involved in amino acid transmembrane transporter activity, extracellular matrix structural constituent, L-amino acid transmembrane transporter activity, and protein binding. Then, the KEGG pathway analysis contributes to study the pathways and functions of the key genes (Figure 6(a)), which mainly were significantly enriched in

### Table 1: Top ten upregulated DEGs in GSE61302 between undifferentiated human primary ADSCs and mature adipocytes.

| ID       | Gene name | Adj. p value | p value  | t       | B       | logFC  |
|----------|-----------|--------------|----------|---------|---------|--------|
| 224354_at| No name   | 1.45E-09     | 1.15E-13 | 3.37E+01| 1.91E+01| 8.85E+00|
| 234432_at| No name   | 2.23E-06     | 7.08E-10 | 1.65E+01| 1.29E+01| 8.75E+00|
| 1555623_at| No name  | 5.86E-11     | 1.16E-15 | 4.88E+01| 2.11E+01| 8.36E+00|
| 1561775_at| No name  | 1.08E-10     | 4.30E-15 | 4.40E+01| 2.06E+01| 7.69E+00|
| 242625_at| RSAD2     | 5.69E-05     | 1.99E-07 | 1.02E+01| 7.65E+00| 5.20E+00|
| 205660_at| OASL      | 1.49E-06     | 3.54E-10 | 1.75E+01| 1.35E+01| 5.15E+00|
| 206336_at| CXCL6     | 1.79E-03     | 7.37E-05 | 5.78E+00| 1.74E+00| 5.07E+00|
| 210797_s_at| OASL  | 1.46E-06     | 2.90E-10 | 1.78E+01| 1.36E+01| 5.02E+00|
| 213797_at| RSAD2     | 2.91E-05     | 5.71E-08 | 1.14E+01| 8.85E+00| 4.82E+00|
| 204533_at| CXCL10    | 6.79E-04     | 1.46E-05 | 6.83E+00| 3.37E+00| 4.50E+00|

### Table 2: Top ten downregulated DEGs in GSE61302 between undifferentiated human primary ADSCs and mature adipocytes.

| ID       | Gene name | Adj. p value | p value  | t       | B       | logFC  |
|----------|-----------|--------------|----------|---------|---------|--------|
| 202768_at| FOSB      | 1.11E-10     | 6.59E-15 | -4.25E+01| 2.05E+01| -6.68E+00|
| 203394_s_at| HES1   | 2.64E-06     | 8.90E-10 | -1.62E+01| 1.27E+01| -5.82E+00|
| 206115_at| EGR3      | 5.00E-06     | 2.48E-09 | -1.49E+01| 1.18E+01| -5.41E+00|
| 218839_at| HEY1      | 2.15E-04     | 2.22E-06 | -8.20E+00| 5.27E+00| -4.85E+00|
| 44783_s_at| HEY1     | 1.34E-04     | 9.50E-07 | -8.86E+00| 6.11E+00| -4.82E+00|
| 201693_s_at| EGR1    | 1.08E-06     | 1.93E-10 | -1.84E+01| 1.40E+01| -4.81E+00|
| 209189_at| FOS       | 1.56E-05     | 1.91E-08 | -1.25E+01| 9.89E+00| -4.64E+00|
| 201890_at| RRM2      | 1.09E-05     | 9.49E-09 | -1.33E+01| 1.05E+01| -4.45E+00|
| 216248_s_at| NR4A2  | 5.83E-05     | 2.08E-07 | -1.02E+01| 7.60E+00| -4.44E+00|
| 233180_at| No name   | 6.39E-05     | 2.50E-07 | -1.00E+01| 7.42E+00| -4.24E+00|

### Table 3: Top 20 hub genes in the PPI networks.

| Rank | Name       | Score |
|------|------------|-------|
| 1    | CTNNB1     | 80    |
| 2    | AURKA      | 37    |
| 3    | FOS        | 36    |
| 4    | MKI67      | 33    |
| 5    | VWF        | 32    |
| 5    | PECAM1     | 32    |
| 5    | RRM2       | 32    |
| 5    | ANLN       | 32    |
| 9    | IGF1       | 30    |
| 10   | H2AFX      | 29    |
| 10   | UBE2C      | 29    |
| 12   | THBS1      | 28    |
| 12   | LMNB1      | 28    |
| 12   | MCM2       | 28    |
| 15   | NCAPG      | 27    |
| 15   | NUSAP1     | 27    |
| 17   | ITGB2      | 26    |
| 17   | CDH5       | 26    |
| 19   | NCAPH      | 25    |
| 19   | UHRF1      | 25    |
the signal pathways of ECM-receptor interaction, focal adhesion, and Rap1 signaling pathway.

To further gain our understanding of the pathway interactions under the study, we revealed the direct connections between pathways of interesting and highlight communities (clusters) of pathways through a bioinformatics approach based on graph theory and the edge betweenness clustering algorithm [22–24]. Wnt signaling pathway was identified according to KEGG repository to be highly connected to pathways related to cell–cell adhesion (adherens junction), cell–ECM adhesion (focal adhesion), and the prosurvival pathways of Rap1, MAPK, and PI3K-AKT. (Figure 6(b)).

3.6. hADSC-Exo Promote Adipogenic Differentiation of ADSC in Adipose Grafts. Cell differentiation assays were used to further validate the specific effects of hADSC-Exo contributing to adipogenic differentiation and showed that the adipogenic differentiation capacity of ADSCs were preserved and promoted better in the hADSCs-Exo group compared with the HFF-Exo group (Figure 6(c)). The result demonstrated that hADSCs-Exo could maintain and promoted the adipogenic differentiation ability of ADSC to promote the retention of fat grafts.

**Figure 6:** hADSC-Exo promoted adipogenic differentiation of ADSC in adipose grafts. (a) The category of “KEGG enrichment” of the target DEGs. (B) Clusters of pathways each one presented by a different color. The black lines are the connections between nodes that form the identified clusters, while the red ones are those excluded by the algorithm. (c) Cell adipogenic differentiation assays showed that hADSC-Exo significantly promote ADSC adipogenic differentiation. (d, e) The expression levels of β-catenin in fat grafts cotransplanted with hADSC-Exo or HFF-Exo. (f) A schematic diagram shows how hADSC-Exo promotes the angiogenesis of fat grafts and maintains the adipogenic differentiation ability of ADSC to promote the retention of fat grafts.
in the hADSCs-Exo compared with the HFF-Exo group (p < 0.05) (Figures 6(d) and 6(e)). The result suggested that hADSC-Exo may regulate the Wnt/β-catenin pathway to improve the adipogenesis in fat grafts.

4. Discussion

Adipose tissue is particularly sensitive to the ischemic environment, where it is susceptible to necrosis and apoptosis [25]. After fat transplantation, the graft must rebuild its blood supply to survive. Unfortunately, most fat grafts are necrotic, liquefied, and resorbed due to difficulties in reestablishing blood supply [26]. Therefore, early vascular regeneration of fat grafts is promoted as an essential strategy to improve the survival of fat grafts.

Stem cell therapy has high application value in promoting vascularization, but the risk of promoting tumor formation and the difficulty of transformation technology greatly limit its clinical application [27, 28]. Therefore, the search for key active components that can be used directly by replacement stem cells and have angiogenic effects can minimize the above potential problems. Accumulating evidences show that exosomes derived from stem cells have great potential for the treatment of tissue injury, infections, and ischemic diseases [29–31]. Meanwhile, the application of stem cell exosome is free of side effects such as malignancy, risk of vascular occlusion, and immunogenicity, indicating that stem cell exosome-based regenerative therapies are safe and have promising applications [32]. Previous studies have shown that hADSC-Exo repair ischemic tissue disease through provascular regeneration, and our previous work also found that hADSC-Exo can significantly promote the angiogenesis of artificial prefabricated dermis flap [14, 33]. However, whether hADSC-Exo can improve adipose graft survival by promoting adipose graft angiogenesis and its underlying mechanism is not yet clear.

To clarify the effect of hADSC-Exo on adipose graft retention, hADSC-Exo and HFF-Exo were cotransplanted with adipose grafts under the skin of nude mice in this study and observed that hADSC-Exo have a better retention rate than HFF-Exo (Figure 2). Interestingly, we observed that the weight and volume of fat grafts decreased gradually over time in both groups, which could be attributed to the progression of fat grafting, mainly involving cysts, calcification, nodules, fat necrosis, fibrosis, and survival, and eventually stabilization [26, 34, 35]. In addition, fat number and integrity of adipose grafts were significantly higher in the hADSC-Exo group than in the HFF-Exo group (Figures 3(a) and 3(b)). Then, CD31+ and Ki67 immunohistochemistry were used to observe the degree of graft vascularization and the number of proliferating cells and showed that hADSC-Exo group had better vascularization and proliferating cell numbers compared to the HFF-Exo group. Notably, hADSC-Exo was also able to promote the proliferation and migration of HUVEC in vitro, and the protein expression extent of VEGFA was also more significant in adipose grafts in the hADSC-Exo group, which indicates that hADSC-Exo could promote the neovascularization of fat grafts, suggesting that hADSC-Exo could improve retention by promoting graft vascularization.

Adipose tissue is rich in ADSC, which is more resistant to ischemia and hypoxia at the early stage of fat grafting compared with mature adipocytes, vascular endothelial cells, and other and blood-derived cells [36], and is able to regenerate adipose tissue through adipogenesis, angiogenesis, and paracrine effects [37]. In the study, we observed better adipose retention and adipose integrity in the hADSC-Exo group, the ability of hADSC-Exo to promote adipogenic differentiation of ADSC and thus replenish adipose grafts that aroused our interest. Peroxisome proliferator-activated receptor gamma (PPARγ), a major regulator of adipogenesis, plays a dominant role in adipocyte differentiation and acts as a transcription factor expressed in mature adipocytes [38]. Numerous studies have shown that adipose cells apparently cannot form without PPARγ [39–41]. Therefore, we observed the immunofluorescence staining result of PPARγ in two groups of fat grafts and indicated that hADSC-Exo can significantly promote the formation of adipocytes in fat grafts. Indeed, activation of adipose stem cells promotes the survival of fat cells in the regenerated area [26]. However, the potential mechanisms by which hADSC-Exo promote adipogenic differentiation of ADSC are not yet clear.

We hypothesize that hADSC-Exo may target key genes regulating pro-ADSC lipogenic differentiation through its enriched miRNAs. To clarify the potential mechanism, the gene expression microarray datasets of hADSC during in vitro adipogenic differentiation (GSE61302) were downloaded from the GEO database in our study, and 1970 DEGs were identified by differential analysis between undifferentiated human primary ADSCs and mature adipocytes. Meanwhile, our previous study found a total of 43 DE-miRNAs between hADSC-Exo and HFF-Exo. Subsequently, we made an intersection between the target genes predicted by DE-miRNAs and the DEGs to basically identify the key DEGs that may be affected by hADSC-Exo in the process of adipogenic differentiation of ADSC. Then, we explored the biological functions of these genes in adipogenic differentiation through GO annotation and KEGG pathway enrichment analysis. Interestingly, these key genes were directly related to the biological processes of extracellular matrix organization and mainly involved in the signal pathways of ECM-receptor interaction, focal adhesion, and Rap1 signaling pathway. ECM is a multifunctional network, consisting of all kinds of proteins, proteoglycans, and glycosaminoglycans, that regulates stem cell differentiation through reciprocal interactions between cells and components of the ECM [42–44]. The development of preadipocytes to mature adipocytes is accompanied by the remodeling and specific changes of ECM in the process of adipogenic differentiation [45]. Yeung et al. [46] found that the inactivation of Rap1 signaling pathway can promote adipocyte differentiation.

Hub genes as high node degree genes in the PPI network may also play an important role in the development of adipogenic differentiation. Through the analysis of the node degree algorithm in the PPI network, several hub genes with high degree were obtained. Notably, CTNNB1, the largest degree gene in the network, encodes beta-catenin 1 protein.
and is also a key regulator of Wnt signaling that interacts with E-cadherin and actin cytoskeleton to mediate cell–cell adhesion [47]. Previous studies showed that the activation of Wnt/β-catenin signaling can suppress the adipogenic differentiation [48, 49]. In addition, Reggio et al. observed that WNT5a repressed PPARγ expression and adipogenesis through the activation of β-catenin signaling [50]. Numerous studies have shown that the activation of PPARγ is associated with a reduction in β-catenin levels [51, 52]. Consistently, our study found downregulation of β-catenin expression and upregulation of PPARγ in hADSC-Exo cotransplanted adipose grafts. Finally, a graph clustering approach was used to expand the relationship between pathways and confirmed our line of investigation demonstrating that Wnt signaling pathway are highly connected to the pathways involved in cell–cell adhesion (adherens junctions, cell–ECM adhesion (focal adhesion), and are also being connected to the prosurvival pathways of Rap1, MAPK, and PI3K-AKT. Our results provide new insights into the molecular mechanism underlying the role of ADSC-Exo in the survival of fat grafts (Figure 6(f)). However, there were also certain limits in our study. For example, there did not involve the specific miRNA engaged in this pathway in hADSC-Exo; thus, the targeting mechanism is not enough strong. Whereafter, we will use single-cell sequencing technology to compare the cellular and molecular components involved in regeneration in fat grafts, so as to further explore the mechanism of fat graft survival.

5. Conclusion

In summary, our findings suggest that hADSC-Exo promotes the angiogenesis of fat grafts and maintains the adipogenic differentiation ability of ADSC to promote the retention of fat grafts and provides a theoretical basis for the clinical translation of hADSC-Exo in fat grafting.

Data Availability

The next-generation sequencing data used to support the findings of this study were supplied by Yuchong Wang under license and so cannot be made freely available.

Conflicts of Interest

The authors have declared that no competing interest exists.

Authors’ Contributions

Kexin Chen, Jiachao Xiong, and Sha Xu contributed equally to this work. Kexin Chen and Jiachao Xiong designed, performed experiments, analyzed data, and wrote the manuscript. Sha Xu and Minliang Wu performed experiments. Chunyu Xue and Chuan Lv edited manuscript. Yuchong Wang and Minjuan Wu conceived, designed experiments, and reviewed/edited the manuscript. And all authors approved the final version of the manuscript.

Acknowledgments

This study was financed by the National Key Research and Development Program of China Stem Cell and Translational Research Key Projects (grant No. 2018YFA0108301), Shanghai Municipal Commission of Health and Family Planning Clinical Research Program (20184Y0113), and National Natural Science Foundation of China (grant No. 81871578).

References

[1] M. S. Ko, J. Y. Jung, I. S. Shin et al., “Effects of expanded human adipose tissue-derived mesenchymal stem cells on the viability of cryopreserved fat grafts in the nude mouse,” International Journal of Medical Sciences, vol. 8, no. 3, pp. 231–238, 2011.

[2] Y. H. Shim and R. H. Zhang, “Literature review to optimize the autologous fat transplantation procedure and recent technologies to improve graft viability and overall outcome: a systematic and retrospective analytic approach,” Aesthetic Plastic Surgery, vol. 41, no. 4, pp. 815–831, 2017.

[3] E. Roca, D. L. Penn, M. G. Safain, W. T. Burke, J. P. Castlen, and E. R. Laws, “Abdominal fat graft for sellar reconstruction: retrospective outcomes review and technical note,” Operative Neurosurgery, vol. 16, no. 6, pp. 667–674, 2019.

[4] K. Yoshimura, H. Eto, H. Kato, K. Doi, and N. Aoi, “In vivo manipulation of stem cells for adipose tissue repair/reconstruction,” Regenerative Medicine, vol. 6, no. 6s, pp. 33–41, 2011.

[5] B. Bonilauri, A. C. Camillo-Andrade, M. D. M. Santos, J. S. S. G. Fischer, P. C. Carvalho, and B. Dallagiovanna, “Proteogenomic analysis reveals proteins involved in the first step of adipogenesis in human adipose-derived stem cells,” Stem Cells International, vol. 2021, Article ID 3168428, 14 pages, 2021.

[6] S. C. Guo, S. C. Tao, W. J. Yin, X. Qi, T. Yuan, and C. Q. Zhang, “Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model,” Theranostics, vol. 7, no. 1, pp. 81–96, 2017.

[7] C. Harding, J. Heuser, and P. Stahl, “Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes,” The Journal of Cell Biology, vol. 97, no. 2, pp. 329–339, 1983.

[8] J. Xiong, B. Ji, L. Wang et al., “Human adipose-derived stem cells promote seawater-immersed wound healing by activating skin stem cells via the EGFR/MEK/ERK pathway,” Stem Cells International, vol. 2019, Article ID 7135974, 16 pages, 2019.

[9] F. Preisner, U. Leimer, S. Sandmann, I. Zoernig, G. Germann, and E. Koellensperger, “Impact of human adipose tissue-derived stem cells on malignant melanoma cells in an in vitro co-culture model,” Stem Cell Reviews and Reports, vol. 14, no. 1, pp. 125–140, 2018.

[10] F. J. Vizoso, N. Eiro, S. Cid, J. Schneider, and R. Perez-Fernandez, “Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine,” International Journal of Molecular Sciences, vol. 18, no. 9, p. 1852, 2017.

[11] L. Guo and N. Guo, “Exosomes: potent regulators of tumor malignancy and potential bio-tools in clinical application,” Critical Reviews in Oncology/Hematology, vol. 95, no. 3, pp. 346–358, 2015.
Q. Lei, T. Liu, F. Gao et al., “Microvesicles as potential biomarkers for the identification of senescence in human mesenchymal stem cells,” *Theranostics*, vol. 7, no. 10, pp. 2673–2689, 2017.

S. Rani, A. E. Ryan, M. D. Griffin, and T. Ritter, “Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications,” *Molecular Therapy*, vol. 23, no. 5, pp. 812–823, 2015.

J. Xiong, Z. Liu, M. Wu, M. Sun, Y. Xia, and Y. Wang, “Comparison of proangiogenic effects of adipose-derived stem cells and foreskin fibroblast exosomes on artificial dermis prefabricated flaps,” *Stem Cells International*, vol. 2020, Article ID 5293850, 14 pages, 2020.

P. Li, M. Kaslan, S. H. Lee, J. Yao, and Z. Gao, “Progress in exosome isolation techniques,” *Theranostics*, vol. 7, no. 3, pp. 789–804, 2017.

L. Zhang, P. Xu, X. Wang et al., “Activin B regulates adipose-derived mesenchymal stem cells to promote skin wound healing via activation of the MAPK signaling pathway,” *The International Journal of Biochemistry & Cell Biology*, vol. 87, pp. 69–76, 2017.

A. Y. Ma, S. W. Xie, J. Y. Zhou, and Y. Zhu, “Noregostrol acetate suppresses human endometrial cancer R195-2 cells proliferation in vitro and in vivo possibly related to upregulating expression of SUFU and Wnt7a,” *International Journal of Molecular Sciences*, vol. 18, no. 7, article 1337, 2017.

D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” *Nucleic Acids Research*, vol. 47, no. D1, pp. D607–D613, 2019.

D. W. Huang, B. T. Sherman, Q. Tan et al., “DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists,” *Nucleic Acids Research*, vol. 35, pp. W169–W175, 2007.

L.-H. Huang, C.-S. Rau, S.-C. Wu et al., “Identification and characterization of HDAC3-derived exosome proteins from different isolation methods,” *Journal of Cellular and Molecular Medicine*, vol. 25, no. 15, pp. 7436–7450, 2021.

L. Claesson-Welsh and M. Welsh, “VEGFA and tumour angiogenesis,” *Journal of Internal Medicine*, vol. 273, no. 2, pp. 114–127, 2013.

M. E. J. Newman and M. Girvan, “Finding and evaluating community structure in networks,” *Physical Review E, Statistical, Nonlinear, and Soft Matter Physics*, vol. 69, no. 2, article 026113, 2004.

E. Y. Chen, C. M. Tan, Y. Kou et al., “Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool,” *BMC Bioinformatics*, vol. 14, no. 1, p. 128, 2013.

M. V. Kuleshov, M. R. Jones, A. D. Rouillard et al., “Enrichr: a comprehensive gene set enrichment analysis web server 2016 update,” *Nucleic Acids Research*, vol. 44, no. W1, pp. W90–W97, 2016.

H. Eto, H. Kato, H. Suga et al., “The fate of adipocytes after nonvascularized fat grafting,” *Plastic and Reconstructive Surgery*, vol. 129, no. 5, pp. 1081–1092, 2012.

L. L. Q. Pu, “Mechanisms of fat graft survival,” *Annals of Plastic Surgery*, vol. 77, Supplement 1, pp. S84–S86, 2016.

J. M. Yu, E. S. Jun, Y. C. Bae, and J. S. Jung, “Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo,” *Stem Cells and Development*, vol. 17, no. 3, pp. 463–474, 2008.

L. Zhao, T. Johnson, and D. Liu, “Therapeutic angiogenesis of adipose-derived stem cells for ischemic diseases,” *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 125, 2017.

O. G. De Jong, B. W. M. Van Balkom, R. M. Schifferers, C. V. C. Bouten, and M. C. Verhaar, “Extracellular vesicles: potential roles in regenerative medicine,” *Frontiers in Immunology*, vol. 5, p. 608, 2014.

L. Shukla, Y. Yuan, R. Shayan, D. W. Greening, and T. Karnezis, “Fat therapeutics: the clinical capacity of adipose-derived stem cells and exosomes for human disease and tissue regeneration,” *Frontiers in Pharmacology*, vol. 11, p. 158, 2020.

W. Zhang, X. Bai, B. Zhao et al., “Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway,” *Experimental Cell Research*, vol. 370, no. 2, pp. 333–342, 2018.

C.-L. Chang, H.-H. Chen, K.-H. Chen et al., “Adipose-derived mesenchymal stem cell-derived exosomes markedly protected the brain against sepsis syndrome induced injury in rat,” *American Journal of Translational Research*, vol. 11, no. 7, pp. 3955–3971, 2019.

X. Zhang, Y. Jiang, Q. Huang et al., “Exosomes derived from adipose-derived stem cells overexpressing glyoxalase-1 protect endothelial cells and enhance angiogenesis in type 2 diabetic mice with limb ischemia,” *Stem Cell Research & Therapy*, vol. 12, no. 1, p. 403, 2021.

J. Laloze, A. Varin, J. Gilhodes et al., “Cell-assisted lipotransfer: friend or foe in fat grafting? Systematic review and meta-analysis,” *Journal of Tissue Engineering and Regenerative Medicine*, vol. 12, no. 2, pp. e1237–e1250, 2018.

L. E. Kokai, T. L. Jones, R. Silovash et al., “Optimization and standardization of the immunodeficient mouse model for assessing fat grafting outcomes,” *Plastic and Reconstructive Surgery*, vol. 140, no. 6, pp. 1185–1194, 2017.

H. Suga, H. Eto, N. Aoi et al., “Adipose tissue remodeling under ischemia: death of adipocytes and activation of stem/progenitor cells,” *Plastic and Reconstructive Surgery*, vol. 126, no. 6, pp. 1911–1923, 2010.

B. D. Rinker and K. S. Vyas, “Do stem cells have an effect when we fat graft?,” *Annals of Plastic Surgery*, vol. 76, Supplement 4, pp. S359–S363, 2016.

T. Garin-Shkolnik, A. Rudich, G. S. Hotamisligil, and M. Rubinstein, “FABP4 attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues,” *Diabetes*, vol. 63, no. 3, pp. 900–911, 2014.

E. D. Rosen, C.-H. Hsu, X. Wang et al., “C/EBPa induces adipogenesis through PPARγ: a unified pathway,” *Genes & Development*, vol. 16, no. 1, pp. 22–26, 2002.

I. Barroso, M. Gurnell, V. E. Crowley et al., “Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension,” *Nature*, vol. 402, no. 6764, pp. 880–883, 1999.

J. Berger, H. V. Patel, J. Woods et al., “A PPARγ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus,” *Molecular and Cellular Endocrinology*, vol. 162, no. 1-2, pp. 57–67, 2000.

H. Li, M. Bao, and Y. Nie, “Extracellular matrix-based biomaterials for cardiac regeneration and repair,” *Heart Failure Reviews*, vol. 26, no. 5, pp. 1231–1248, 2021.
X. Wang, Z. Chen, B. Zhou et al., “Cell-sheet-derived ECM coatings and their effects on BMSCs responses,” ACS Applied Materials & Interfaces, vol. 10, no. 14, pp. 11508–11518, 2018.

H. Ragelle, A. Naba, B. L. Larson et al., “Comprehensive proteomic characterization of stem cell-derived extracellular matrices,” Biomaterials, vol. 128, pp. 147–159, 2017.

E. C. M. Mariman and P. Wang, “Adipocyte extracellular matrix composition, dynamics and role in obesity,” Cellular and Molecular Life Sciences: CMLS, vol. 67, no. 8, pp. 1277–1292, 2010.

F. Yeung, C. M. Ramírez, P. A. Mateos-Gomez et al., “Nontelomeric role for Rap1 in regulating metabolism and protecting against obesity,” Cell Reports, vol. 3, no. 6, pp. 1847–1856, 2013.

K. Willert and K. A. Jones, “Wnt signaling: is the party in the nucleus?,” Genes & Development, vol. 20, no. 11, pp. 1394–1404, 2006.

I. Takada, A. P. Kouzmenko, and S. Kato, “Molecular switching of osteoblastogenesis versus adipogenesis: implications for targeted therapies,” Expert Opinion on Therapeutic Targets, vol. 13, no. 5, pp. 593–603, 2009.

W. P. Cawthorn, A. J. Bree, Y. Yao et al., “Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a ß-catenin-dependent mechanism,” Bone, vol. 50, no. 2, pp. 477–489, 2012.

A. Reggio, M. Rosina, A. Palma et al., “Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/ß-catenin axis,” Cell Death & Differentiation, vol. 27, no. 10, pp. 2921–2941, 2020.

A. Vallée and Y. Lecarpentier, “Crosstalk between peroxisome proliferator-activated receptor gamma and the canonical WNT/ß-catenin pathway in chronic inflammation and oxidative stress during carcinogenesis,” Frontiers in Immunology, vol. 9, p. 745, 2018.

Q. Zuo, J. He, S. Zhang et al., “PPARγ coactivator-1α suppresses metastasis of hepatocellular carcinoma by inhibiting Warburg effect by PPARγ-dependent WNT/ß-catenin/pyruvate dehydrogenase kinase isozyme 1 Axis,” Hepatology, vol. 73, no. 2, pp. 644–660, 2021.